{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:31:51Z","timestamp":1781530311654,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"DOI":"10.7759\/cureus.66877","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:24:51Z","timestamp":1723659891000},"source":"Crossref","is-referenced-by-count":2,"title":["Use of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Oligometastatic Lung Adenocarcinoma: Leveraging CT-Guided Online Adaptive Radiotherapy"],"prefix":"10.7759","author":[{"given":"Nicholas","family":"Eustace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colton","family":"Ladbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagus","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borna","family":"Maraghechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Oligometastatic non-small cell lung cancer: current management","volume":"7","author":"Rom\u00e1n-Jobacho A","year":"2021","unstructured":"Rom\u00e1n-Jobacho A, Hern\u00e1ndez-Miguel M, Garc\u00eda-Anaya MJ, G\u00f3mez-Mill\u00e1n J, Medina-Carmona JA, Otero-Romero A. Oligometastatic non-small cell lung cancer: current management. J Clin Transl Res. 2021, 7:311-9.","journal-title":"J Clin Transl Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez DR","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr, Lee JJ, et al.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016, 17:1672-82. 10.1016\/S1470-2045(16)30532-0","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang XS","year":"2023","unstructured":"Wang XS, Bai YF, Verma V, et al.. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer. J Natl Cancer Inst. 2023, 115:742-8. 10.1093\/jnci\/djac015","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng P","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, et al.. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023, 184:109681. 10.1016\/j.radonc.2023.109681","journal-title":"Radiother Oncol"},{"key":"ref5","article-title":"Radiobiology for the radiologist","author":"Hall EJ","year":"2019","unstructured":"Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Wolters Kluwer, Philadelphia (PA); 2019."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7469","article-title":"Stereotactic body radiation therapy in multiple organ sites","volume":"25","author":"Timmerman RD","year":"2007","unstructured":"Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007, 25:947-52. 10.1200\/JCO.2006.09.7469","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?","volume":"88","author":"Brown JM","year":"2014","unstructured":"Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. Int J Radiat Oncol Biol Phys. 2014, 88:254-62. 10.1016\/j.ijrobp.2013.07.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball D","year":"2019","unstructured":"Ball D, Mai GT, Vinod S, et al.. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019, 20:494-503. 10.1016\/S1470-2045(18)30896-9","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.04.52","article-title":"Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances","volume":"10","author":"Sebastian NT","year":"2018","unstructured":"Sebastian NT, Xu-Welliver M, Williams TM. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. J Thorac Dis. 2018, 10:S2451-64. 10.21037\/jtd.2018.04.52","journal-title":"J Thorac Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62906","article-title":"The first reported case of treating the ultra-central thorax with cone beam computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR)","volume":"16","author":"Zhao S","year":"2024","unstructured":"Zhao S, Beckert R, Zhao X, et al.. The first reported case of treating the ultra-central thorax with cone beam computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR). Cureus. 2024, 16:e62906. 10.7759\/cureus.62906","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64101","article-title":"Ultra-hypofractionated prostate radiotherapy with online adaptive technique: a case report","volume":"16","author":"Yoganathan SA","year":"2024","unstructured":"Yoganathan SA, Riyas M, Sukumaran R, Hammoud R, Al-Hammadi N. Ultra-hypofractionated prostate radiotherapy with online adaptive technique: a case report. Cureus. 2024, 16:e64101. 10.7759\/cureus.64101","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.03.047","article-title":"Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade","volume":"110","author":"Moore C","year":"2021","unstructured":"Moore C, Hsu CC, Chen WM, et al.. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade. Int J Radiat Oncol Biol Phys. 2021, 110:1306-16. 10.1016\/j.ijrobp.2021.03.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1357790","article-title":"Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy","volume":"14","author":"Peng H","year":"2024","unstructured":"Peng H, Deng J, Jiang S, Timmerman R. Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy. Front Oncol. 2024, 14:1357790. 10.3389\/fonc.2024.1357790","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria S","year":"2021","unstructured":"Demaria S, Guha C, Schoenfeld J, et al.. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. J Immunother Cancer. 2021, 9:10.1136\/jitc-2020-002038","journal-title":"J Immunother Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00475","article-title":"Stereotactic body radiotherapy for the management of early-stage non-small-cell lung cancer: a clinical overview","volume":"19","author":"Buchberger DS","year":"2023","unstructured":"Buchberger DS, Videtic GM. Stereotactic body radiotherapy for the management of early-stage non-small-cell lung cancer: a clinical overview. JCO Oncol Pract. 2023, 19:239-49. 10.1200\/OP.22.00475","journal-title":"JCO Oncol Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic GM","year":"2017","unstructured":"Videtic GM, Donington J, Giuliani M, et al.. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017, 7:295-301. 10.1016\/j.prro.2017.04.014","journal-title":"Pract Radiat Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria S","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015, 1:1325-32. 10.1001\/jamaoncol.2015.2756","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang Z","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022, 7:258. 10.1038\/s41392-022-01102-y","journal-title":"Signal Transduct Target Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen WS","year":"2019","unstructured":"Theelen WS, Peulen HM, Lalezari F, et al.. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019, 5:1276-82. 10.1001\/jamaoncol.2019.1478","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281200-use-of-personalized-ultra-fractionated-stereotactic-adaptive-radiotherapy-for-oligometastatic-lung-adenocarcinoma-leveraging-ct-guided-online-adaptive-radiotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:24:56Z","timestamp":1723659896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281200-use-of-personalized-ultra-fractionated-stereotactic-adaptive-radiotherapy-for-oligometastatic-lung-adenocarcinoma-leveraging-ct-guided-online-adaptive-radiotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.66877","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}